[go: up one dir, main page]

DE60318089D1 - Protein-tyrosine-kinase-inhibitoren - Google Patents

Protein-tyrosine-kinase-inhibitoren

Info

Publication number
DE60318089D1
DE60318089D1 DE60318089T DE60318089T DE60318089D1 DE 60318089 D1 DE60318089 D1 DE 60318089D1 DE 60318089 T DE60318089 T DE 60318089T DE 60318089 T DE60318089 T DE 60318089T DE 60318089 D1 DE60318089 D1 DE 60318089D1
Authority
DE
Germany
Prior art keywords
alkyl
alkynyl
alkenyl
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318089T
Other languages
English (en)
Other versions
DE60318089T2 (de
Inventor
Wayne R Danter
George Ma
Natalie Lazarowych
Stephen Houldsworth
Martyn Brown
Ghenadie Rusu
Jianhua Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cotinga Pharmaceuticals Inc
Original Assignee
Critical Outcome Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Outcome Technologies Inc filed Critical Critical Outcome Technologies Inc
Publication of DE60318089D1 publication Critical patent/DE60318089D1/de
Application granted granted Critical
Publication of DE60318089T2 publication Critical patent/DE60318089T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60318089T 2002-10-09 2003-10-09 Protein-tyrosine-kinase-inhibitoren Expired - Lifetime DE60318089T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41691102P 2002-10-09 2002-10-09
US416911P 2002-10-09
PCT/CA2003/001524 WO2004033446A1 (en) 2002-10-09 2003-10-09 Protein tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
DE60318089D1 true DE60318089D1 (de) 2008-01-24
DE60318089T2 DE60318089T2 (de) 2008-12-04

Family

ID=32093922

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318089T Expired - Lifetime DE60318089T2 (de) 2002-10-09 2003-10-09 Protein-tyrosine-kinase-inhibitoren

Country Status (8)

Country Link
US (1) US7629347B2 (de)
EP (1) EP1551824B1 (de)
AT (1) ATE380810T1 (de)
AU (1) AU2003273675A1 (de)
CA (1) CA2542007C (de)
DE (1) DE60318089T2 (de)
ES (1) ES2298563T3 (de)
WO (1) WO2004033446A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105875A1 (es) 2015-09-02 2017-11-15 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (Nº 2) LTD Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
US10370356B2 (en) 2015-09-22 2019-08-06 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
KR20180059551A (ko) 2015-10-05 2018-06-04 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서 2-옥소-1,2-디하이드로피리딘-3,5-디카복스아미드 화합물
CN108884070B (zh) 2016-04-07 2021-07-02 葛兰素史克知识产权第二有限公司 作为溴结构域抑制剂的吡啶基衍生物
EP3464242A1 (de) * 2016-05-24 2019-04-10 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridindicarboxamidderivate als bromdomäneninhibitoren
JOP20190192A1 (ar) 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
GB201703282D0 (en) 2017-03-01 2017-04-12 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US660037A (en) * 1899-05-01 1900-10-16 Wellman Seaver Engineering Company Hot-blast stove.
DE3678805D1 (de) 1985-11-08 1991-05-23 Glaxo Group Ltd Indolderivate.
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JPH0558894A (ja) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd 抗腫瘍剤
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0600832A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Diaminobenzoe- und Diaminophthalsäurederivate und ihre Verfahren als Proteinkinase-Inhibitoren
US5618829A (en) * 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
CA2148931A1 (en) * 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1995023141A1 (en) * 1994-02-23 1995-08-31 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE19501481A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
US5932574A (en) * 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
CA2222545A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) * 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
EP0912559B1 (de) * 1996-07-13 2002-11-06 Glaxo Group Limited Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ATE384062T1 (de) * 1996-08-23 2008-02-15 Novartis Pharma Gmbh Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
EP0929553B1 (de) * 1996-10-02 2005-03-16 Novartis AG Pyrimiderivate und verfahren zu ihrer herstellung
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
JPH1180131A (ja) 1997-09-01 1999-03-26 Mitsubishi Chem Corp エチニルピリミジン誘導体
US6184377B1 (en) * 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
ATE401312T1 (de) * 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
ATE272040T1 (de) * 1998-02-06 2004-08-15 Univ Montfort Durch hydroxylierung aktivierte medikamentvorstufen
WO1999055682A1 (en) * 1998-04-29 1999-11-04 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
US20010051628A1 (en) * 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
US6253168B1 (en) * 1998-05-12 2001-06-26 Isis Pharmaceuticals, Inc. Generation of virtual combinatorial libraries of compounds
US6289352B1 (en) * 1998-05-29 2001-09-11 Crystal Decisions, Inc. Apparatus and method for compound on-line analytical processing in databases
CA2342222A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US20010041964A1 (en) * 1998-09-14 2001-11-15 George M. Grass Pharmacokinetic-based drug design tool and method
HU230728B1 (hu) 1998-09-29 2017-12-28 Wyeth Holdings Llc Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (de) 1999-04-08 2005-05-11 Arch Dev Corp Verwendung eines anti-vegf antikörpers zur verstärkung der bestrahlung in der krebstherapie
ATE341341T1 (de) 1999-08-12 2006-10-15 Wyeth Corp Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs
CN1373763A (zh) * 1999-09-15 2002-10-09 沃尼尔·朗伯公司 作为激酶抑制剂的蝶啶酮
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
HK1046276A1 (zh) * 2000-02-05 2003-01-03 Vertex Pharmaceuticals Incorporated 有益的用作erk抑制剂的吡唑组合物
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
BR0109056A (pt) 2000-03-06 2003-06-03 Warner Lambert Co Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas
GB0007657D0 (en) * 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
GB2372562A (en) * 2000-04-26 2002-08-28 Ribotargets Ltd In silico screening
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6489094B2 (en) * 2000-05-31 2002-12-03 Pfizer Inc. Method and device for drug-drug interaction testing sample preparation
US7022484B2 (en) * 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
JP2004504276A (ja) * 2000-06-26 2004-02-12 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン ヒトの皮膚の光老化を防止するためのｅｇｆ−ｒタンパク質チロシンキナーゼ抑制剤の使用
US7067046B2 (en) * 2000-08-04 2006-06-27 Essen Instruments, Inc. System for rapid chemical activation in high-throughput electrophysiological measurements
US6647342B2 (en) * 2000-08-07 2003-11-11 Novodynamics, Inc. Knowledge-based process for the development of materials
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
DE60113286T2 (de) * 2000-10-17 2006-06-22 Merck & Co., Inc. Oral aktive salze mit tyrosinkinaseaktivität
US7759323B2 (en) * 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
US20040193538A1 (en) * 2003-03-31 2004-09-30 Raines Walter L. Receipt processing system and method
CA2429907A1 (en) * 2003-05-27 2004-11-27 Cognos Incorporated Modelling of a multi-dimensional data source in an entity-relationship model

Also Published As

Publication number Publication date
ATE380810T1 (de) 2007-12-15
DE60318089T2 (de) 2008-12-04
CA2542007A1 (en) 2004-04-22
CA2542007C (en) 2010-06-29
ES2298563T3 (es) 2008-05-16
EP1551824B1 (de) 2007-12-12
US7629347B2 (en) 2009-12-08
US20060111371A1 (en) 2006-05-25
AU2003273675A1 (en) 2004-05-04
WO2004033446A1 (en) 2004-04-22
EP1551824A1 (de) 2005-07-13

Similar Documents

Publication Publication Date Title
YU84603A (sh) Novi inhibitori tirozin kinaze
SE0202463D0 (sv) Novel compounds
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
NO20044995L (no) Heterosykliske forbindelser
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO20032625L (no) Indazolyl-substituerte pyrrolinforbindelser som kineaseinhibitorer
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
EA201000093A1 (ru) Производные пиридазинона
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
TW200635585A (en) Monocyclic substituted methanones
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
BRPI0416690A (pt) derivados de pirrol
GB0308201D0 (en) Novel compounds
DE60313339D1 (de) Protein tyrosin kinase inhibitoren
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
MY141020A (en) Novel pparalpha and ppargamma agonists
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
ATE380810T1 (de) Protein-tyrosine-kinase-inhibitoren
EA200500191A1 (ru) Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition